• Je něco špatně v tomto záznamu ?

Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts

B. Aradi, M. Kato, M. Filkova, E. Karouzakis, K. Klein, M. Scharl, C. Kolling, BA. Michel, RE. Gay, EI. Buzas, S. Gay, A. Jüngel,

. 2015 ; 67 (10) : 2624-33.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010055

OBJECTIVE: To investigate the role of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in the pathogenesis of rheumatoid arthritis (RA). METHODS: Synovial tissue samples from patients with RA and patients with osteoarthritis (OA) were stained for PTPN2. Synovial fibroblasts were stimulated with tumor necrosis factor (TNF) and interleukin-1β (IL-1β), lipopolysaccharide (LPS), TRAIL, or thapsigargin. The expression of PTPN2 in synovial fibroblasts and peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and Western blotting. Cell death, the release of IL-6 and IL-8, and the induction of autophagy were analyzed after PTPN2 silencing. Methylated DNA immunoprecipitation analysis was used to evaluate DNA methylation-regulated gene expression of PTPN2. RESULTS: PTPN2 was significantly overexpressed in synovial tissue samples from RA patients compared to OA patients. Patients receiving anti-TNF therapy showed significantly reduced staining for PTPN2 compared with patients treated with nonbiologic agents. PTPN2 expression was higher in RA synovial fibroblasts (RASFs) than in OASFs. This differential expression was not regulated by DNA methylation. PTPN2 was further up-regulated after stimulation with TNF, TNF combined with IL-1β, or LPS. There was no significant difference in basal PTPN2 expression in PBMCs from patients with RA, ankylosing spondylitis, or systemic lupus erythematosus or healthy controls. Most interestingly, PTPN2 silencing in RASFs significantly increased the production of the inflammatory cytokine IL-6 but did not affect levels of IL-8. Moreover, functional analysis showed that high PTPN2 levels contributed to the increased apoptosis resistance of RASFs and increased autophagy. CONCLUSION: This is the first study of PTPN2 in RASFs showing that PTPN2 regulates IL-6 production, cell death, and autophagy. Our findings indicate that PTPN2 is linked to the pathogenesis of RA via synovial fibroblasts.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010055
003      
CZ-PrNML
005      
20160412105731.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/art.39256 $2 doi
024    7_
$a 10.1002/art.39256 $2 doi
035    __
$a (PubMed)26139109
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Aradi, Borbala $u Center of Experimental Rheumatology, University Hospital Zurich, and Zurich Center for Integrative Human Physiology, Zurich, Switzerland. $7 gn_A_00007925
245    10
$a Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts / $c B. Aradi, M. Kato, M. Filkova, E. Karouzakis, K. Klein, M. Scharl, C. Kolling, BA. Michel, RE. Gay, EI. Buzas, S. Gay, A. Jüngel,
520    9_
$a OBJECTIVE: To investigate the role of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in the pathogenesis of rheumatoid arthritis (RA). METHODS: Synovial tissue samples from patients with RA and patients with osteoarthritis (OA) were stained for PTPN2. Synovial fibroblasts were stimulated with tumor necrosis factor (TNF) and interleukin-1β (IL-1β), lipopolysaccharide (LPS), TRAIL, or thapsigargin. The expression of PTPN2 in synovial fibroblasts and peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and Western blotting. Cell death, the release of IL-6 and IL-8, and the induction of autophagy were analyzed after PTPN2 silencing. Methylated DNA immunoprecipitation analysis was used to evaluate DNA methylation-regulated gene expression of PTPN2. RESULTS: PTPN2 was significantly overexpressed in synovial tissue samples from RA patients compared to OA patients. Patients receiving anti-TNF therapy showed significantly reduced staining for PTPN2 compared with patients treated with nonbiologic agents. PTPN2 expression was higher in RA synovial fibroblasts (RASFs) than in OASFs. This differential expression was not regulated by DNA methylation. PTPN2 was further up-regulated after stimulation with TNF, TNF combined with IL-1β, or LPS. There was no significant difference in basal PTPN2 expression in PBMCs from patients with RA, ankylosing spondylitis, or systemic lupus erythematosus or healthy controls. Most interestingly, PTPN2 silencing in RASFs significantly increased the production of the inflammatory cytokine IL-6 but did not affect levels of IL-8. Moreover, functional analysis showed that high PTPN2 levels contributed to the increased apoptosis resistance of RASFs and increased autophagy. CONCLUSION: This is the first study of PTPN2 in RASFs showing that PTPN2 regulates IL-6 production, cell death, and autophagy. Our findings indicate that PTPN2 is linked to the pathogenesis of RA via synovial fibroblasts.
650    _2
$a senioři $7 D000368
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a revmatoidní artritida $x metabolismus $x patologie $7 D001172
650    _2
$a autofagie $x účinky léků $7 D001343
650    _2
$a biologické přípravky $x farmakologie $7 D001688
650    _2
$a kultivované buňky $7 D002478
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x účinky léků $x metabolismus $x patologie $7 D005347
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-1beta $x farmakologie $7 D053583
650    _2
$a interleukin-6 $x metabolismus $7 D015850
650    _2
$a lipopolysacharidy $x farmakologie $7 D008070
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a osteoartróza $x metabolismus $x patologie $7 D010003
650    _2
$a tyrosinfosfatasa nereceptorového typu 2 $x metabolismus $7 D054578
650    _2
$a synoviální membrána $x účinky léků $x metabolismus $x patologie $7 D013583
650    _2
$a protein TRAIL $x farmakologie $7 D053221
650    _2
$a thapsigargin $x farmakologie $7 D019284
650    _2
$a TNF-alfa $x antagonisté a inhibitory $x farmakologie $7 D014409
650    _2
$a upregulace $x účinky léků $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kato, Masaru $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Filkova, Maria $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Karouzakis, Emmanuel $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Klein, Kerstin $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Scharl, Michael $u Zurich Center for Integrative Human Physiology and University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Kolling, Christoph $u Schulthess Clinic, Zurich, Switzerland.
700    1_
$a Michel, Beat A $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Gay, Renate E $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Buzas, Edit I $u Semmelweis University, Budapest, Hungary.
700    1_
$a Gay, Steffen $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Jüngel, Astrid $u Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
773    0_
$w MED00188151 $x 2326-5205 $g Roč. 67, č. 10 (2015), s. 2624-33 $t Arthritis & rheumatology (Hoboken, N.J.)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26139109 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160412105814 $b ABA008
999    __
$a ok $b bmc $g 1113484 $s 934423
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 67 $c 10 $d 2624-33 $i 2326-5205 $m Arthritis & rheumatology $x MED00188151
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace